137 related articles for article (PubMed ID: 18194499)
21. Effects of Helicobacter pylori and nonsteroidal anti-inflammatory drugs on peptic ulcer disease: a systematic review.
Papatheodoridis GV; Sougioultzis S; Archimandritis AJ
Clin Gastroenterol Hepatol; 2006 Feb; 4(2):130-42. PubMed ID: 16469671
[TBL] [Abstract][Full Text] [Related]
22. The relative contribution of NSAIDs and Helicobacter pylori to the aetiology of endoscopically-diagnosed peptic ulcer disease: observations from a tertiary referral hospital in the UK between 2005 and 2010.
Musumba C; Jorgensen A; Sutton L; Van Eker D; Moorcroft J; Hopkins M; Pritchard DM; Pirmohamed M
Aliment Pharmacol Ther; 2012 Jul; 36(1):48-56. PubMed ID: 22554233
[TBL] [Abstract][Full Text] [Related]
23. Role of acid suppressants in prophylaxis of NSAID damage.
Chan FK; Sung JJ
Best Pract Res Clin Gastroenterol; 2001 Jun; 15(3):433-45. PubMed ID: 11403537
[TBL] [Abstract][Full Text] [Related]
24. [Coxib instead of NSAID plus gastric acid inhibitor. Protection for the small intestine].
MMW Fortschr Med; 2004 Mar; 146(13):61. PubMed ID: 15219139
[No Abstract] [Full Text] [Related]
25. Reduced incidence of upper gastrointestinal ulcer complications with the COX-2 selective inhibitor, valdecoxib.
Goldstein JL; Eisen GM; Agrawal N; Stenson WF; Kent JD; Verburg KM
Aliment Pharmacol Ther; 2004 Sep; 20(5):527-38. PubMed ID: 15339324
[TBL] [Abstract][Full Text] [Related]
26. [Peptic ulcer (gastro-duodenal ulcer, acute gastric mucosal lesion, NSAIDs-induced ulcer)].
Matsuhashi N
Nihon Rinsho; 2012 Aug; 70 Suppl 6():553-6. PubMed ID: 23156570
[No Abstract] [Full Text] [Related]
27. NSAID-induced peptic ulcer disease: a critical review of pathogenesis and management.
Scheiman JM
Dig Dis; 1994; 12(4):210-22. PubMed ID: 7851000
[TBL] [Abstract][Full Text] [Related]
28. [Lansoprazole: an analysis of the clinical trials in the 3 years of 1997-1999].
Dobrilla G; Capurso L
Recenti Prog Med; 2000 Apr; 91(4):191-210. PubMed ID: 10804753
[TBL] [Abstract][Full Text] [Related]
29. The relationship between nonsteroidal anti-inflammatory drug use and peptic ulcer disease.
Graham DY
Gastroenterol Clin North Am; 1990 Mar; 19(1):171-82. PubMed ID: 2184127
[TBL] [Abstract][Full Text] [Related]
30. Use of NSAIDs and infection with Helicobacter pylori--what does the rheumatologist need to know?
Kiltz U; Zochling J; Schmidt WE; Braun J
Rheumatology (Oxford); 2008 Sep; 47(9):1342-7. PubMed ID: 18477642
[TBL] [Abstract][Full Text] [Related]
31. Prevention of NSAID-induced GI mucosal injury.
Gerritz S; Newton WP
J Fam Pract; 1997 Feb; 44(2):130-1. PubMed ID: 9040509
[No Abstract] [Full Text] [Related]
32. Non-steroidal anti-inflammatory drugs and peptic ulcer.
Langman MJ
Hepatogastroenterology; 1992 Feb; 39 Suppl 1():37-9. PubMed ID: 1577395
[TBL] [Abstract][Full Text] [Related]
33. [Treatment and prevention of gastrointestinal complications caused by non-steroidal antiphlogistic agents].
Rybár I; Kriska M; Vavrecka A; Hyrdel R; Rovenský J
Cas Lek Cesk; 1999 Nov; 138(22):675-80. PubMed ID: 10746025
[TBL] [Abstract][Full Text] [Related]
34. [How to reduce the risks of NSAIDs].
Gross M
MMW Fortschr Med; 2008 Jul; 150(28-31):50-3; quiz 54. PubMed ID: 19006892
[No Abstract] [Full Text] [Related]
35. Acute NSAID-related transmural duodenitis and extensive duodenal ulceration.
Hashash JG; Atweh LA; Saliba T; Chakhachiro Z; Al-Kutoubi A; Tawil A; Barada KA
Clin Ther; 2007 Nov; 29(11):2448-52. PubMed ID: 18158085
[TBL] [Abstract][Full Text] [Related]
36. Evidence-based clinical practice guidelines for peptic ulcer disease 2015.
Satoh K; Yoshino J; Akamatsu T; Itoh T; Kato M; Kamada T; Takagi A; Chiba T; Nomura S; Mizokami Y; Murakami K; Sakamoto C; Hiraishi H; Ichinose M; Uemura N; Goto H; Joh T; Miwa H; Sugano K; Shimosegawa T
J Gastroenterol; 2016 Mar; 51(3):177-94. PubMed ID: 26879862
[TBL] [Abstract][Full Text] [Related]
37. Trends in the prevalence of peptic ulcer disease and Helicobacter pylori infection in family physician-referred uninvestigated dyspeptic patients in Hong Kong.
Xia B; Xia HH; Ma CW; Wong KW; Fung FM; Hui CK; Chan CK; Chan AO; Lai KC; Yuen MF; Wong BC
Aliment Pharmacol Ther; 2005 Aug; 22(3):243-9. PubMed ID: 16091062
[TBL] [Abstract][Full Text] [Related]
38. NSAID-associated dyspepsia and ulcers: a prospective cohort study in primary care.
Hollenz M; Stolte M; Leodolter A; Labenz J
Dig Dis; 2006; 24(1-2):189-94. PubMed ID: 16699277
[TBL] [Abstract][Full Text] [Related]
39. ANTI-ULCEROGENIC EFFICACY AND MECHANISMS OF EDIBLE AND NATURAL INGREDIENTS IN NSAID-INDUCED ANIMAL MODELS.
Bi W; Hu L; Man MQ
Afr J Tradit Complement Altern Med; 2017; 14(4):221-238. PubMed ID: 28638885
[TBL] [Abstract][Full Text] [Related]
40. Underutilization of preventive strategies in patients receiving NSAIDs.
Sturkenboom MC; Burke TA; Dieleman JP; Tangelder MJ; Lee F; Goldstein JL
Rheumatology (Oxford); 2003 Nov; 42 Suppl 3():iii23-31. PubMed ID: 14585915
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
